nach oben

Digestive Diseases and Sciences

Erschienen in:

01.05.2008 | Original Paper

Angiotensin II Type 1 Receptor Antagonist Suppress Angiogenesis and Growth of Gastric Cancer Xenografts

verfasst von: Wei Huang, Yun-Lin Wu, Jie Zhong, Feng-Xiang Jiang, Xiang-long Tian, Li-Fen Yu

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Angiotensin II (Ang II) has been reported to promote tumor progression, tumor growth and angiogenesis in many cancers. We previously observed that angiotensin II type1 receptors (AT1R) were upregulated in human gastric cancer and may be involved in the progression of gastric cancer. We studied the effects of AT1R antagonist on angiogenesis and growth in gastric cancer xenografts to observe the mechanism action of AT1R in the gastric cancer. The results showed that the growth of gastric cancer cells was significantly suppressed by treatment with AT1R antagonist. In vivo, TCV-116, at doses of both 2 and 5 mg/kg/day, significantly suppressed tumor growth in mice (47.3 and 70.2%). Microvessel density was significantly decreased by TCV-116 (3.4 ± 0.9 and 2.8 ± 0.5 per field) compared with the control group (12.9 ± 1.1 per field), and VEGF expression was significantly suppressed by AT1R antagonist. These results demonstrate that AT1R plays an important role in the progression of gastric cancer. Suppression tumor angiogenesis could be one of the mechanisms by which AT1R antagonist suppresses the growth of gastric cancer. These findings also provide a theoretical basis for the future clinical application of AT1R antagonist against gastric cancer.

Sun XD, Mu R, Zhou YS, Dai XD, Zhang SW, Huangfu XM, Sun J, Li LD, Lu FZ, Qiao YL (2004) Analysis of mortality rate of stomach cancer and its trend in 20 years in China. Zhonghua Zhong Liu Za Zhi 26:4–9PubMed

Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299PubMedCrossRef

Escobar E, Rodriguez-Reyna TS, Arrieta O et al (2004) Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 4:385–399CrossRef

Smith GR, Missailidis S (2004) Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm 1:1–12CrossRef

Ino K, Shibata K, Kajiyama H et al (2006) Manipulating the angiotensin system–new approaches to the treatment of solid tumors. Expert Opin Biol Ther 6:243–255PubMedCrossRef

Volpert O et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679PubMedCrossRef

Hii S et al (1998) Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 77:880–883PubMed

Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) The angiotensin- I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7:1073–1078PubMed

Prontera C et al (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81:761–766PubMedCrossRef

10.

Dinh DT, Frauman AG, Somers GR et al (2002) Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT (1) receptor expression in benign prostatic hyperplasia. J Pathol 196:213–219PubMedCrossRef

11.

Ino K, Shibata K, Kajiyama H et al (2006) Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumor angiogenesis and patient survival. Br J Cancer 94:552–560PubMedCrossRef

12.

Lam KY, Leung PS (2002) Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumors. Eur J Endocrinol 146:567–572PubMedCrossRef

13.

Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158:1633–1637PubMed

14.

Egami K, Murohara T, Shimada T et al (2003) Role of host angiotensin II type 1receptor in tumor angiogenesis and growth. J Clin Invest 112:67–75PubMed

15.

Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M (2003) Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 14:2061–2067CrossRef

16.

Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M (2005) Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26:271–279PubMedCrossRef

17.

Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175–203PubMedCrossRef

18.

Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515PubMedCrossRef

19.

Kondo K, Muramatsu M, Okamoto Y et al (2006) Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93:36–42PubMedCrossRef

20.

Muramatsu M, Katada J, Hayashi I, Majima M (2000) Chymase as a proangiogenic factor. J Biol Chem 275:5545–5552PubMedCrossRef

21.

Fujimoto Y, Sasaki T, Tsuchida A et al (2001) Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495:197–200PubMedCrossRef

22.

Uemura H, Ishiguro H, Nakaigawa N et al (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2:1139–1147PubMed

23.

Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J (2001) AT1 receptor is present in glioma cells its blockage reduces the growth of rat glioma. Br J Cancer 85:1396–1399PubMedCrossRef

24.

Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M (2002) Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 294:441–447PubMedCrossRef

25.

Miyajima A, Kosaka T, Asano T et al (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62:4176–4179PubMed

26.

Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai1 M (2006) Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 12:2888–2893PubMedCrossRef

27.

Suganuma T, Ino K, Shibata K et al (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 11:2686–2694PubMedCrossRef

28.

Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M (2007) Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 67:41–49PubMedCrossRef

29.

Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y (2005) Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 10:405–410PubMedCrossRef

Titel: Angiotensin II Type 1 Receptor Antagonist Suppress Angiogenesis and Growth of Gastric Cancer Xenografts
verfasst von: Wei Huang
Yun-Lin Wu
Jie Zhong
Feng-Xiang Jiang
Xiang-long Tian
Li-Fen Yu
Publikationsdatum: 01.05.2008
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 5/2008
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-0009-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Comparative Studies on Expression of α-Smooth Muscle Actin in Hepatic Stellate Cells in Chronic Hepatitis B and C

Lack of Reversal of Carditis by PPI Therapy Only Means That Acid in Refluxate is Not Responsible for Carditis

Prognostic and Predictive Value of Thymidylate Synthase Expression in Colon Cancer

Chemo-embolization for Unresectable Hepatocellular Carcinoma with Different Sizes of Embolization Particles

Is Rotavirus a Hepatotropic Virus?

A Role of Cell Apoptosis in Lipopolysaccharide (LPS)-induced Nonlethal Liver Injury in d-galactosamine (d-GalN)-sensitized Rats